» Articles » PMID: 7525569

Mutations Along Transmembrane Segment II of the NK-1 Receptor Affect Substance P Competition with Non-peptide Antagonists but Not Substance P Binding

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1994 Nov 11
PMID 7525569
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Mutational analysis of the NK-1 receptor indicates that residues involved in non-peptide antagonist binding cluster around the outer portion of transmembrane segments (TM) V and VI. In contrast mutations affecting the binding of the natural peptide agonist, substance P, are scattered in the exterior part of the receptor. Recently it was reported that a number of mutations in TM-II also seriously impair substance P binding. Here we confirm that Ala substitutions for these residues located on a hydrophilic helical face of TM-II basically eliminate substance P binding to the NK-1 receptor, provided that a radiolabeled non-peptide antagonist is used as radioligand. Surprisingly, radiolabeled substance P bound well to all these mutant receptors and was displaced with only slightly reduced affinity by the unlabeled peptide and by the non-peptide antagonists. The wild-type homologous NK-2 receptor displayed properties similar to those observed in the mutated NK-1 receptors, i.e. concomitant high affinity binding of radiolabeled agonist peptide (in this case neurokinin A), yet low affinity, G-protein independent competition of unlabeled peptide with radiolabeled non-peptide antagonist. It is concluded that substitutions in TM-II of the NK-1 receptor do not affect the high affinity binding of substance P but instead block the ability of the peptides to compete for non-peptide antagonist binding. It is suggested that certain mutations can impair interchange between receptor conformations that each bind different ligands with high affinity.

Citing Articles

Novel agonist and antagonist radioligands for the GLP-2 receptor. Useful tools for studies of basic GLP-2 receptor pharmacology.

Gadgaard S, van der Velden W, Schiellerup S, Hunt J, Gabe M, Windelov J Br J Pharmacol. 2021; 179(9):1998-2015.

PMID: 34855984 PMC: 9303331. DOI: 10.1111/bph.15766.


Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.

van der Velden W, Heitman L, Rosenkilde M ACS Pharmacol Transl Sci. 2020; 3(2):179-189.

PMID: 32296761 PMC: 7155193. DOI: 10.1021/acsptsci.0c00012.


Selective Allosteric Modulation of N-Terminally Cleaved, but Not Full Length CCL3 in CCR1.

Larsen O, Luckmann M, van der Velden W, Oliva-Santiago M, Brvar M, Ulven T ACS Pharmacol Transl Sci. 2020; 2(6):429-441.

PMID: 32259075 PMC: 7088985. DOI: 10.1021/acsptsci.9b00059.


GPCR Modulation in Breast Cancer.

Lappano R, Jacquot Y, Maggiolini M Int J Mol Sci. 2018; 19(12).

PMID: 30513833 PMC: 6321247. DOI: 10.3390/ijms19123840.


Molecular Mechanism of Action for Allosteric Modulators and Agonists in CC-chemokine Receptor 5 (CCR5).

Karlshoj S, Amarandi R, Larsen O, Daugvilaite V, Steen A, Brvar M J Biol Chem. 2016; 291(52):26860-26874.

PMID: 27834679 PMC: 5207192. DOI: 10.1074/jbc.M116.740183.